ScoreWhy is ERIS Lifesciences Ltd ?
1
High Management Efficiency with a high ROCE of 16.70%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.32 times
3
Poor long term growth as Operating profit has grown by an annual rate 18.11% of over the last 5 years
4
The company has declared Positive results for the last 3 consecutive quarters
- OPERATING CF(Y) Highest at Rs 1,065.01 Cr
- OPERATING PROFIT TO INTEREST(Q) Highest at 5.82 times
- NET SALES(Q) Highest at Rs 792.41 cr
5
With ROCE of 14.2, it has a Expensive valuation with a 4.4 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 8.37%, its profits have risen by 19.3% ; the PEG ratio of the company is 2.7
6
High Institutional Holdings at 26.57%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
7
Consistent Returns over the last 3 years
- Along with generating 8.37% returns in the last 1 year, the stock has outperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to ERIS Lifescience should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is ERIS Lifescience for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
ERIS Lifescience
8.37%
0.26
32.82%
Sensex
4.83%
0.41
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
21.37%
EBIT Growth (5y)
18.11%
EBIT to Interest (avg)
38.25
Debt to EBITDA (avg)
1.59
Net Debt to Equity (avg)
0.75
Sales to Capital Employed (avg)
0.58
Tax Ratio
22.46%
Dividend Payout Ratio
0.28%
Pledged Shares
16.93%
Institutional Holding
26.57%
ROCE (avg)
17.25%
ROE (avg)
16.76%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
51
Industry P/E
34
Price to Book Value
6.89
EV to EBIT
30.68
EV to EBITDA
22.12
EV to Capital Employed
4.37
EV to Sales
7.88
PEG Ratio
2.68
Dividend Yield
0.47%
ROCE (Latest)
14.24%
ROE (Latest)
13.45%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend18What is working for the Company
OPERATING CF(Y)
Highest at Rs 1,065.01 Cr
OPERATING PROFIT TO INTEREST(Q)
Highest at 5.82 times
NET SALES(Q)
Highest at Rs 792.41 cr
PBDIT(Q)
Highest at Rs 288.21 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 36.37%
PBT LESS OI(Q)
At Rs 169.86 cr has Grown at 36.37%
PAT(Q)
At Rs 120.19 cr has Grown at 31.2%
EPS(Q)
Highest at Rs 8.82
-3What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 7.31 times
DEBTORS TURNOVER RATIO(HY)
Lowest at 4.63 times
Loading Valuation Snapshot...
Here's what is working for ERIS Lifescience
Operating Cash Flow - Annually
Highest at Rs 1,065.01 Cr and Grown
each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (Rs Cr)
Operating Profit to Interest - Quarterly
Highest at 5.82 times
in the last five quartersMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Net Sales - Quarterly
Highest at Rs 792.41 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 288.21 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 36.37%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 169.86 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 169.86 cr has Grown at 36.37%
Year on Year (YoY)MOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 120.19 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 120.19 cr has Grown at 31.2%
Year on Year (YoY)MOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 8.82
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for ERIS Lifescience
Inventory Turnover Ratio- Half Yearly
Lowest at 7.31 times and Fallen
each half year in the last five half yearly periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debtors Turnover Ratio- Half Yearly
Lowest at 4.63 times
in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
